The Effect of Mindfulness on Cognition and Emotion Following Acquired Brain Injury

NCT ID: NCT03231488

Last Updated: 2017-08-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

46 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-07-31

Study Completion Date

2018-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Can mindfulness help with attention and emotion difficulties after a brain injury?

People who have a brain injury often have problems with their attention and emotions. This study will see if a short mindfulness task can help with these problems. So far, there are not many studies looking at this and those that do show mixed results. When being mindful someone is aware of their attention and focuses on the present moment without passing judgement. This study focuses on over-selectivity and selective attention to threat after a brain injury. These are two concepts involved in attention and emotion problems. Over-selectivity is when someone focuses on only one thing around them and misses other key things. Selective attention to threat is when someone's focus is drawn to something around them that is seen as threatening. This has been shown to cause and keep anxious feelings going. This research will see if a short mindfulness task can help those with a brain injury by reducing overselectivity and selective attention to threat on two tasks. Participants will be recruited from NHS and non-NHS brain injury services. The study will take around two hours to complete for each participant. In summary, this study looks to see if a specific mindfulness exercise can be helpful for specific attention and emotion problems. It could be a first step in making treatment better and giving more treatment options for those with a brain injury.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Injuries, Brain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Mindfulness intervention

Group Type EXPERIMENTAL

Mindfulness intervention

Intervention Type OTHER

A 10 minute mindfulness of breath exercise

Control intervention (unfocused attention)

Group Type ACTIVE_COMPARATOR

Control intervention (unfocused attention)

Intervention Type OTHER

A 10 minute unfocused attention intervention - participants are asked to let their mind wander on anything that comes to mind.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Mindfulness intervention

A 10 minute mindfulness of breath exercise

Intervention Type OTHER

Control intervention (unfocused attention)

A 10 minute unfocused attention intervention - participants are asked to let their mind wander on anything that comes to mind.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged 18 years and over
* Medical evidence of ABI with attention or executive functioning difficulties, such as difficulties with planning, inhibition or attention
* Time since ABI to be 9 months or greater • ABI severity to be moderate to severe, determined by the Mayo classification system (Malec et al., 2007). This is classification system is frequently used to determine ABI severity and is standard practice to record at the acute stage of care when the individual is admitted to hospital. This means there must be evidence of one or more of the following in medical notes: the individual's lowest Glasgow Coma Scale (GCS) score is less than 13, there is a loss of consciousness of at least 30 minutes immediately following ABI and post traumatic amnesia (PTA) is at least 24 hours in length. If there is no evidence of this in the medical notes, then there must be evidence that the individual has clinically significant difficulties resulting from their ABI to have needed a referral to brain injury services.
* There are self-reported or clinician-identified emotional difficulties to adjusting to circumstances post-ABI

Exclusion Criteria

* Significant, severe and enduring presence of mental health difficulties or substance misuse that would prevent valid engagement in experimental tasks
* Perceptual, language, communication, reading or motor difficulties that would prevent valid engagement in experimental tasks
* The presence of developmental or acquired dyslexia affecting the automatic reading of words in the emotional Stroop
* Severe cognitive difficulties that would prevent valid engagement in experimental tasks
* Presence of pre-existing or comorbid disorders that may affect cognitive functioning (other than ABI) that would prevent valid engagement in experimental tasks
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Cambridge University Hospitals NHS Foundation Trust

OTHER

Sponsor Role collaborator

Cambridgeshire Community Services NHS Trust

OTHER

Sponsor Role collaborator

Cambridgeshire and Peterborough NHS Foundation Trust

OTHER

Sponsor Role collaborator

NORFOLK COMMUNITY HEALTH AND CARE NHS TRUST

UNKNOWN

Sponsor Role collaborator

NORTHAMPTONSHIRE HEALTHCARE NHS FOUNDATION TRUST

UNKNOWN

Sponsor Role collaborator

Headway Cambridgeshire

UNKNOWN

Sponsor Role collaborator

Headway Essex

UNKNOWN

Sponsor Role collaborator

Headway Norfolk and Waveney

UNKNOWN

Sponsor Role collaborator

Icanho, Livability

UNKNOWN

Sponsor Role collaborator

Brain Injury Rehabilitation Trust

OTHER

Sponsor Role collaborator

St Andrew's Healthcare

OTHER

Sponsor Role collaborator

Partnerships in Care

OTHER

Sponsor Role collaborator

University of East Anglia

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Cambridge University Hospitals Nhs Foundation Trust

Cambridge, , United Kingdom

Site Status NOT_YET_RECRUITING

Cambridgeshire Community Services Nhs Trust

Cambridge, , United Kingdom

Site Status RECRUITING

Headway Cambridgeshire

Cambridge, , United Kingdom

Site Status NOT_YET_RECRUITING

Brain Injury Rehabilitation Trust

Ely, , United Kingdom

Site Status NOT_YET_RECRUITING

Headway Essex

Essex, , United Kingdom

Site Status RECRUITING

Headway Norfolk & Waveney

Norfolk, , United Kingdom

Site Status RECRUITING

Norfolk Community Health and Care Nhs Trust

Norfolk, , United Kingdom

Site Status RECRUITING

Northamptonshire Healthcare Nhs Foundation Trust

Northampton, , United Kingdom

Site Status RECRUITING

Partnerships in Care

Northampton, , United Kingdom

Site Status NOT_YET_RECRUITING

St Andrews Healthcare

Northampton, , United Kingdom

Site Status NOT_YET_RECRUITING

Cambridgeshire and Peterborough Nhs Foundation Trust

Peterborough, , United Kingdom

Site Status NOT_YET_RECRUITING

Icanho, Livability

Stowmarket, , United Kingdom

Site Status NOT_YET_RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Katrina Vicentijevic

Role: CONTACT

07498045055

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Katrina Vicentijevic

Role: primary

07498045055

Katrina Vicentijevic

Role: primary

07498045055

Katrina Vicentijevic

Role: primary

07498045055

Katrina Vicentijevic

Role: primary

07498045055

Katrina Vicentijevic

Role: primary

07498045055

Katrina Vicentijevic

Role: primary

07498045055

Katrina Vicentijevic

Role: primary

07498045055

Katrina Vicentijevic

Role: primary

07498045055

Katrina Vicentijevic

Role: primary

07498045055

Katrina Vicentijevic

Role: primary

07498045055

Katrina Vicentijevic

Role: primary

07498045055

Katrina Vicentijevic

Role: primary

07498045055

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IRAS project ID: 213205

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.